AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03462823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteoconductive scaffold-hamstring tendon composite repair
Description: The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).
Study NCT03462823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring tendon-only repair
Description: ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
Study NCT02784132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video diversion
Description: The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
Study NCT01112670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 100 mg x 1 dose
Study NCT01112670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 40 mg x 5 doses
Study NCT04630600 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Normal waiting room without an aquarium
Study NCT03314662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
Description: The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
Study NCT02286219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS102
Description: Experimental
Study NCT00535587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00535587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyridostigmine
Study NCT00535587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placibo
Study NCT00535587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Study NCT02122718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Study NCT02122718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01901874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting with the GORE® Carotid Stent
Study NCT00305552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THALIDOMIDE
Description: THALIDOMIDE
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab Placebo
Description: Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Placebo
Description: Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone Placebo
Description: Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Placebo
Description: Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
Study NCT01791153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
Study NCT02621801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training for Residents (SMART-R)
Description: The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
Study NCT02621801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management and Resiliency Training for Residents (SMART-R)
Description: The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
Study NCT03142516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
Study NCT04630600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partially-equipped aquarium in the waiting area
Description: Waiting room with a partially-equipped Aquarium
Study NCT03142516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
Study NCT04630600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fully-equipped aquarium in the waiting area
Description: Waiting room with a fully-equipped Aquarium
Study NCT03142516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
Study NCT03142516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
Study NCT01227655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: Capsules will be used.
Study NCT01227655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator
Study NCT01227655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Study NCT01227655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa
Study NCT01227655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: DOPA decarboxylase inhibitor (DDCI)
Study NCT01227655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbidopa
Description: DOPA decarboxylase inhibitor (DDCI)
Study NCT01227655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benserazide
Description: DOPA decarboxylase inhibitor
Study NCT01227655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benserazide
Description: DOPA decarboxylase inhibitor
Study NCT02093221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 180 mg/kg Alpha1-PI
Study NCT02093221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90 mg/kg Alpha1-PI
Study NCT02093221 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02604472 — intervention group
Intervention type: OTHER
Intervention: CCRT
Description: Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
Study NCT02604472 — intervention group
Intervention type: OTHER
Intervention: IC+CCRT
Description: Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
Study NCT02399098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional focus
Description: The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
Study NCT00586482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
Study NCT00586482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lozenge
Description: Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
Study NCT00586482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abstinence Advisement
Description: A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
Study NCT00586482 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Abstinence Advisement
Description: A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
Study NCT02884323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko™ device
Description: The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
Study NCT00557024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: radiofrequency ablation
Study NCT00557024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy after RFA
Description: radiotherapy after RFA
Study NCT02603978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BASICS
Description: A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
Study NCT02603978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bystander and Social Norms
Description: A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
Study NCT02603978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined BASICS and Bystander
Description: A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
Study NCT01715896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
Study NCT01715896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Description: Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
Study NCT02080832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 20 mg or 40 mg daily for 8 weeks
Study NCT02080832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 8 weeks
Study NCT00992368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reduction mammaplasty
Description: patients submitted to reduction mammaplasty
Study NCT02303951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Run-In: Day 1-21 60 mg od orally Triple-Treatment (week 5 ongoing): 60 mg od 21/7 orally (3 weeks on drug, 1 week off)
Study NCT02303951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Triple-Treatment (week 5 ongoing): 840 mg Q2W i.v
Study NCT01398072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
Study NCT01398072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: An oral dose of 250 mg once daily three times a week (every other day).
Study NCT01398072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: An oral dose of 100 mg once daily.
Study NCT01398072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of one table once daily.
Study NCT03312712 — intervention group
Intervention type: RADIATION
Intervention: PET/CT scan
Description: PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs.
Study NCT02387593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOCUFF
Description: One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
Study NCT00983918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
Study NCT00983918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
Study NCT00983918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
Study NCT00983918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
Study NCT01947088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
Study NCT01947088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
Study NCT05016830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral transcranial direct current stimulation
Description: A direct current is applied with two electrodes (cathode and anode) in specific parts of the skull. In this case the anode was over the occipital area to target the amblyopic cortex, while the cathode was over the contralateral side, targeting the fellow cortex.
Study NCT01276717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Carfilzomib
Description: Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
Study NCT01276717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
Study NCT03179163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril Pill
Description: ACEi+SH
Study NCT03179163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Pill
Description: ACEi
Study NCT03179163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: diuretic
Study NCT02662166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR imaging
Description: 3 T MRI of the urinary bladder
Study NCT02247219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling and education individually and in groups
Description: The counselling method is based om Motivational Interviewing
Study NCT02247219 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counselling and education individually and in groups
Description: The counselling method is based om Motivational Interviewing
Study NCT04891965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ART24
Description: Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10\^9 CFU/capsule. Subjects will receive 1 capsule daily.
Study NCT04891965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
Study NCT03008239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense sensor
Description: The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
Study NCT03008239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom Sensor
Description: Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
Study NCT02700438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl trinitrate ointment
Description: Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
Study NCT02700438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urgent PC Neuromodulation System®
Description: Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.